INTRODUCTION
With increased survival of HIV-infected patients, there has been a significant shift in the causes of morbidity and mortality from AIDS-defining conditions (infections and AIDS-related malignancies) to non-AIDS-defining conditions, principally cardiovascular diseases, liver-related complications, and non-AIDS malignancies. Osteoporosis and increased fracture risk is also a major cause of morbidity in these patients [1] [2] [3] .
Like many non-AIDS complications, the pathogenesis of increased fracture risk among HIVinfected patient is incompletely understood. It likely involves patient factors (overrepresentation of ''traditional'' risk factors); direct effects of HIV infection, HIV-associated inflammation and immune activation; and effects of antiretroviral therapy (ART) [4] . Chronic hepatitis C virus (HCV) coinfection (present in up to a third of HIV-infected patients [5] ) likely contributes to the increased fracture risk, because recent observational studies have demonstrated HIV/HCV coinfected patients have an increased fracture incidence compared to HCV monoinfected, HIV monoinfected, and uninfected persons [6] .
In this article, we will review the epidemiologic and clinical evidence for increased fracture risk among HIV/HCV coinfected patients and discuss potential mechanisms of osteoporosis and increased fracture risk associated with HCV coinfection.
FRACTURE INCIDENCE IN HIV/HEPATITIS C VIRUS COINFECTION
In several large cohort studies from North America, Europe, Australia, and Asia, an estimated 15-30% of HIV-infected patients are coinfected with chronic HCV because of shared risk factors [6] [7] [8] [9] [10] . The incidences of liver-related and nonliver-related complications of chronic HCV infection are higher among HIV/HCV coinfected patients than HCV monoinfected patients [11, 12] . In addition to its ability to induce liver fibrosis, chronic HCV infection is also associated with extra-hepatic complications, particularly abnormalities in bone metabolism and increased fracture risk, which may contribute to morbidity among HIV/HCV coinfected patients as this group ages [2,6,13 & ,14 & ].
HIV and HCV infections have been associated with an increased risk of osteoporotic fracture compared to uninfected persons [6, 15, 16] . Osteoporotic fractures were more common in HIV/HCV coinfected compared to HIV monoinfected patients in several reports [2, 8, [16] [17] [18] (Table 1) . Rates of hip fractures are also significantly higher in HIV/HCV coinfected compared to HIV monoinfected, HCV monoinfected, and uninfected persons (hazard ratios ranging from 1.2 to 2.4) [6] (Table 1) . Although cirrhosis and advanced liver disease are known risk factors for osteoporosis [19] , the deleterious impact of HCV on BMD [20] and fracture risk [2] appears to occur before the development of severe liver fibrosis or cirrhosis, although the exact mechanism(s) remain to be elucidated.
MECHANISMS OF INCREASED BONE FRAGILITY IN HIV/HEPATITIS C VIRUS COINFECTION
Low bone mineral density (BMD) is a recognized metabolic complication of HIV [1, 21] and chronic hepatitis C virus (HCV) infection [19, 22] . Among HIV-infected patients, BMD further decreases 2-6% over the first 2 years of ART initiation [23] [24] [25] . HCV coinfection has been associated with further reductions in BMD among HIV-infected patients in some [26-28,29 & ,30] , but not all studies [30-32,33 & ]. These findings raise the possibility that the higher fracture risk observed in patients with chronic HCV infection might not be because of low BMD alone, but could involve other mechanism(s).
Some factors related to HIV and chronic HCV have been hypothesized to contribute to skeletal fragility. HIV-related inflammation, ART-related toxicity, increased prevalence of tobacco/alcohol use, and traditional osteoporosis risk factors exacerbated by HIV contribute to low BMD and increased fracture risk in HIV [4] . Chronic HCV-associated inflammatory cytokines, particularly tumor necrosis factor-a, might inhibit bone formation and increase bone resorption [34, 35] . The development of HCVrelated hepatic decompensation might further contribute to a decrease in BMD by impairing production of factors (e.g. 25-hydroxyvitamin D, insulin-like growth factor-1 [IGF-1]) that promote bone formation and mineralization [19, 22] . Each of the potential mechanisms that have been explored will be discussed below ( Fig. 1 ).
Overrepresentation of 'traditional' fracture risk factors
Observations of an increased fracture risk in HIV/ HCV coinfected patients led to speculations that the risk is likely because of either behavioral factors (such as substance abuse and intoxication leading to traumas) or an overrepresentation of 'traditional' fracture risk factors in these populations [8] . This
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was reinforced by the observation that, unlike HIVmonoinfected patients, HIV/HCV coinfected patients had a higher incidence of 'high-energy' fractures (not deemed to be osteoporotic in nature) [8] . These findings suggest that HCV-infected patients might be more likely to engage in activities leading to traumatic fractures, or that fracture risk factors such as tobacco use, alcohol consumption, and corticosteroid use, are more prevalent among chronic HCV-infected patients [36, 37] .
Role of severity of liver disease
Although advanced liver disease is associated with hepatic osteodystrophy, several studies have shown that the incidence of osteoporosis and increased fracture risk are not associated with severity of liver disease in chronic HCV-infected patients. In a large cohort of HIV-infected U.S. Veterans, HCV coinfection remained a strong independent osteoporotic fracture predictor, even after controlling for the severity of liver diseases (assessed by aspartate aminotransferase-to-platelet ratio index [APRI]) and presence of cirrhosis [adjusted hazard ratio, 1.31; 95% confidence interval (CI), 1.12-1.52] [2] . Similarly, El-Maouche et al. [38] showed that severity of liver disease was not associated with risk of osteoporosis in an HIV/HCV coinfected cohort. Taken together, these findings suggest that the severity of liver fibrosis is, at best, a weak determinant of increased fracture risk among HIV/HCV coinfected patients.
Increased inflammation and immune activation
Although increased inflammation in HIV and HCV has been associated with increased rates of non-AIDS complications [39] and extra-hepatic complications [40] , it remains unclear if chronic inflammation contributes to increased bone turnover and fragility. In one recent cross-sectional study using tibia peripheral quantitative computed tomography (pQCT) to evaluate skeletal parameters in ARTtreated HIV/HCV coinfected, HCV monoinfected, and ART-treated HIV monoinfected women, coinfected participants had substantially lower tibial trabecular volumetric BMD and diminished cortical dimensions with significant endocortical bone deficits compared to healthy reference participants. These findings support the hypothesis that HIVmediated and HCV-mediated chronic inflammation might contribute to the structural bone deficits observed in this group. Moreover, studies of patients with other chronic inflammatory conditions, particularly inflammatory bowel disease [41, 42] and rheumatoid arthritis [43] , have demonstrated a similar pattern of trabecular bone loss and endocortical thinning. In addition, median tumor necrosis factor-a levels in this study were found to be higher among coinfected than either HCV monoinfected or HIV monoinfected women, further suggesting the contribution of chronic inflammation. Tumor necrosis factor-a can reduce trabecular and cortical bone formation by inhibiting osteoblast differentiation, inhibiting osteoblast collagen secretion, and inducing osteoblast apoptosis [34, 35] . This cytokine can also promote accelerated trabecular and cortical bone resorption by inducing expression of receptor activator of nuclear factor kappa B ligand, which stimulates osteoclast activation and inhibits osteoblast apoptosis [44, 45] . Additional studies are needed to evaluate the potential contribution of chronic inflammation to bone deficits and associated metabolic and body composition abnormalities among HIV/HCV coinfected patients.
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Vitamin D deficiency
Observational studies also suggest that HIV/HCV coinfected patients are more likely to have low serum 25-hydroxyvitamin D levels [46] , and vitamin D deficiency has been shown to be associated with liver disease severity in HIV/HCV coinfected patients [47 & ,48] . However, it remains unclear whether lower vitamin D levels are associated with either decreased BMD or increased fracture risk in the setting of HIV/HCV coinfection [49] .
Bone turnover in HIV and hepatitis C virus
To assess the impact of HIV and HCV on skeletal health, a recent cross-sectional study compared BMD, bone turnover markers, inflammatory markers, and sex hormones between HIV/HCV coinfected, HIV monoinfected, HCV monoinfected, and uninfected men of similar age, race, and body mass index distribution [29 & ]. HIV infection was associated with increased bone turnover, with significant elevations in serologic markers of bone formation (osteocalcin) and resorption (collagen type 1 crosslinked C-telopeptide) [29 & ]. Conversely, chronic HCV was not associated with increased bone resorption (Fig. 2) , and its effect on BMD reduction was largely independent of bone turnover markers. These results are corroborated by another study of 40-year-old to 60-year-old chronic HCV-infected patients without cirrhosis that demonstrated high rates of osteoporosis, but BMD was not associated with systemic inflammatory markers or markers of bone resorption (i.e., collagen type 1 cross-linked C-telopeptide) [50 & ]. These findings could have significant implications in the prevention and management of osteoporosis in chronic HCV-infected patients. As bone turnover is not increased among HCV monoinfected patients, use of pharmacological agents to decrease bone resorption may be neither safe nor effective among chronic HCV patients.
Regulation of bone metabolism in HIV and hepatitis C virus: role of insulin-like growth factor-1 and sex hormones IGF-1 [51] [52] [53] and the sex steroids testosterone and estradiol play key roles in osteogenesis and bone resorption [54] , but their contribution to bone health in relation to HIV and HCV infections remain unclear.
IGF-1 contributes to osteogenesis from mesenchymal stem cells, promoting osteoblast survival and differentiation [51, 52] . It is produced primarily by the liver, and its production can be impaired in decompensated cirrhosis [55] , potentially resulting in reduced bone formation. In one study, IGF-1 was lower in chronic HCV-infected than uninfected patients and median levels decreased as APRI scores increased [29 & ]. However, IGF-1 was not associated with bone resorption or BMD [29 & ]. It is, therefore, not likely an important mechanism by which chronic HCV infection contributes to low BMD.
Significant differences have been observed in the effects of estradiol and testosterone on osteogenesis using human-bone-marrow-derived mesenchymal stem cells from men and women [54, 56] . It is unclear whether HIV or HCV modulate these effects. Chronic HCV-infected patients have higher levels of total estradiol and testosterone, likely because of increased levels of steroid hormone binding globulin [29 & ]. Bioavailable testosterone and estradiol were associated with higher markers of bone formation, but neither were associated with low BMD [29 & ].
MANAGING FRACTURE RISK IN HIV/ HEPATITIS C VIRUS COINFECTED PATIENTS
Assessment of fracture risk in HIV/hepatitis C virus: can we do better?
As mentioned above, although not associated with significantly lower BMD than HIV or HCV monoinfection in most studies [27, 31, 32, 57, 58] , HIV/ HCV coinfection has been consistently shown to predict much greater fracture risk than HIV monoinfection (hazard ratios ranging from 1. evaluated to predict fracture risk for a variety of conditions. These methods should be explored in the context of HIV/HCV coinfection and HCV monoinfection.
Trabecular bone score Trabecular bone score (TBS) is a novel measurement of bone microarchitecture from dual-energy X-ray absorptiometry (DXA) images. In TBS, numbers and amplitudes of pixel-to-pixel gray-level variations of a projection of a BMD image is used to infer the three-dimensional density of trabecular structure using mathematical 'experimental variograms' [59 & ]. Although not a direct measurement of bone microarchitecture, TBS is a close approximation of three-dimensional bone characteristics and has recently been shown to be a practical, noninvasive, surrogate technique for the assessment of cancellous bone microarchitecture in premenopausal women and in men with osteoporosis [60] . There is growing recognition that TBS can predict risk of fracture in conditions such as glucocorticoid therapy [61] , subclinical hypercortisolism [62] , and diabetes mellitus [63, 64] , which are associated with increased fracture risk but not decreased BMD. These conditions might cause a deleterious effect on bone structure that is not captured by BMD alone, but may be detected by TBS. Similarly, TBS might improve fracture risk prediction in other conditions associated with secondary osteoporosis, such as HCV or HIV.
In a recent study by Martinez et al. [65] , compared to antiretroviral naïve patients, those receiving a boosted protease inhibitor (PI) with or without tenofovir (TDF) had significantly lower BMD (P < 0.03), but much lower TBS (P < 0.0001). Furthermore, only those receiving boosted PI with or without TDF had lower BMD than antiretroviralnaïve patients whereas all regimens were associated with lower TBS. These results suggest that TBS might improve fracture risk prediction among HIV-infected and HIV/HCV coinfected patients and highlight bone effects of ART not detected by BMD alone.
High-resolution peripheral quantitative computed tomography
Other direct or indirect measurements of cortical or trabecular properties are now being used to assess bone strength and predict fracture risk in postmenopausal women and conditions of increased bone fragility. Assessment of bone quality has also been performed in conditions with increased bone fragility using high-resolution peripheral quantitative computed tomography (HRpQCT). HRpQCT allows for three-dimensional assessment of bone macroarchitecture and microarchitecture (e.g. cortical porosity and trabecular connectivity) of the distal radius and tibia. This technology has shown increased cortical porosity in postmenopausal women [66] , patients with type 2 diabetes mellitus [67] , and with HIV-1 infection [68] .
Using tibial HRpQCT, Lo Re et al. [33 & ] conducted a cross-sectional analysis of 50 HIV/HCV coinfected, 51 HCV monoinfected, and 50 HIV monoinfected women. The study found that compared with 263 healthy reference patients, HIV/HCV coinfected women had decreased tibial trabecular volumetric BMD, diminished cortical dimensions, and significant endocortical bone loss. Also, trabecular volumetric BMD was lower in coinfected than in HCV or HIV monoinfected participants. More analyses of HRpQCT in patients with HIV/HCV will help to further elucidate the mechanisms of the structural defects leading to increased bone fragility in these patients.
In-vivo microindentation
Recently, a new device has been developed that can perform in-vivo measurement of bone material properties (bone material strength index) using a 'microindentation' technique [69] . This technique has been used to assess bone quality in postmenopausal women and in those with type 2 diabetes mellitus [70] . Future studies should evaluate its use among HIV/HCV coinfected patients.
Management of fracture risk in HIV/hepatitis C virus
If corroborated by other studies, the lack of association of elevated bone turnover with decreased BMD in chronic HCV infection could have important implications in the prevention and management of osteoporosis in these patients. The most commonly used antiosteoporosis agents, bisphosphonates, are antiresorptive agents. As bone turnover is not increased in HCV monoinfected patients, it is unclear whether pharmacologic means of decreasing bone resorption would be well tolerated and effective in chronic HCV-infected patients. Data in postmenopausal women show that the antifracture efficacy of bisphosphonates is significantly lower among both osteoporotic and nonosteoporotic women with lower baseline levels of bone turnover markers [71] . It also remains unclear if achieving viral cure of chronic HCV infection (i.e. sustained virologic response) will significantly improve bone health, and this should be a focus of future observational studies.
Primary prevention
The National Osteoporosis Foundation recommends DXA scans for postmenopausal women aged at least 65 years and men aged at least 70 years [72] , and for younger individuals with conditions that predispose to bone loss and increased fracture risk. HIV infection is now listed among these conditions. Guidelines for the management of fracture risk in HIV-infected patients have also been published [4,73 & ]. The indications for treatment are not different from those of the general population, except that the threshold for DXA evaluation is lower for patients with HIV infection (50 years) [4,73 & ]. At present, there are no specific recommendations for osteoporosis screening or management for HIV/ HCV coinfected patients.
The main interventions aimed at treating osteoporosis and reducing the risk of fragility fractures include dietary and supplemental calcium and vitamin D, weight-bearing exercises, and pharmacological agents (mostly bisphosphonates and the biological agent denosumab). The adherence to and effectiveness of recommended measures for preventing fractures among HIV-infected and HCVinfected populations have not been evaluated.
Secondary prevention
The National Osteoporosis Foundation 2014 Clinicians' Guide recommends pharmacologic therapy for postmenopausal women and men aged at least 50 years with a previous hip or vertebral fracture, osteoporosis, or osteopenia with a high FRAX score (i.e. 10-year probability of a hip fracture 3% or 10-year probability of a major osteoporosis-related fracture 20%). TBS is a proven osteoporotic fracture predictor, even after adjustment for BMD, and is now included as an independent risk factor in the FRAX algorithm for fracture risk prediction [74] .
Impact of antiviral therapy for chronic hepatitis C virus infection
For patients with HIV/HCV, limited data suggest that treatment of HCV could have significant benefits in decreasing fracture risk. Successful HCV clearance in response to interferon (IFN) therapy was associated with a two-thirds reduction in the risk of bone fracture in postmenopausal women with osteoporosis and chronic HCVinduced liver disease [75] . In another cohort of HCV monoinfected patients, antiviral therapy with PEGylated -IFN led to significant on-treatment increases in lumbar spine and hip BMD and reduction in serologic markers of bone resorption irrespective of subsequent treatment response [76] .
The impact of anti-HCV therapy with pegylated IFN and ribavirin on bone turnover among HIV/ HCV coinfected patients was recently investigated to explore the relative effect of HCV virologic control and the use of pegylated IFN on bone health. ]. These data suggest that successful treatment of chronic HCV could result in improvements in HCV-associated bone fragility. However, it remains unclear whether these declines in BTM are pegylated IFN-related or will be observed with current IFN-free direct-acting antiviral regimens. It is also unknown if these changes posttreatment are durable and if they will lead to improvements in BMD or TBS. Given the significantly increased fracture risk associated with chronic HCV, improvement of bone health could be a significant added advantage of antiviral therapy for chronic HCV infection.
CONCLUSION
HIV/HCV coinfection is associated with significantly increased fracture risk, even in the absence of advanced hepatitis fibrosis or cirrhosis. However, the mechanisms for the low BMD and increased risk in this setting have not been fully elucidated. New tools to assess bone quality, such as the trabecular bone score, pQCT, and in-vivo microindentation, may help improve understanding of the mechanisms of HCV-associated skeletal fragility in HIVinfected persons. Additional studies are needed to determine the effects of antiosteoporosis medications and direct-acting antivirals for the treatment of chronic HCV infection on HIV/HCV coinfected patients' bone health. respectively, for their assistance with the studies described. Conflicts of interest R.B. is currently receiving a grant (AI424-552) from Bristol Myers Squibb and has served on ad-hoc scientific advisory boards for BMS, Merck & Co., Theratechnologies and Gilead Sciences. The remaining authors have no conflicts of interest.
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